« Back to Record
Citation APA

Gebhart, G., Tol, J., Oyen, W. J. G., Vugts, D., Hoekstra, O. O., Schröder, C. P., Menke-van der Houven van Oordt, C. W., Guiot, T., Brouwers, A. A., Awada, A., de Vries, E. G. E. L. E., Lamberts, L. L., Flamen, P., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M. T., & Aftimos, P. (2016). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial. Annals of oncology, 27(4), mdv577, 619-624. doi:10.1093/annonc/mdv577


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/231106

Gebhart, G., Tol, J., Oyen, W. J. G., Vugts, D., Hoekstra, O. O., Schröder, C. P., Menke-van der Houven van Oordt, C. W., Guiot, T., Brouwers, A. A., Awada, A., de Vries, E. G. E. L. E., Lamberts, L. L., Flamen, P., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., Stroobants, S., Huizing, M. T., & Aftimos, P. (2016). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial. Annals of oncology, 27(4), mdv577, 619-624. doi:10.1093/annonc/mdv577